TSE:HBP Helix BioPharma (HBP) Stock Price, News & Analysis C$0.96 0.00 (0.00%) As of 05/2/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Helix BioPharma Stock (TSE:HBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Helix BioPharma alerts:Sign Up Key Stats Today's RangeC$0.96▼C$0.9650-Day RangeC$0.77▼C$0.9852-Week RangeC$0.50▼C$1.35VolumeN/AAverage Volume2,639 shsMarket CapitalizationC$50.90 millionP/E RatioN/ADividend Yield1.50%Price TargetN/AConsensus RatingN/A Company OverviewHelix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.Read More… Receive HBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HBP Stock News HeadlinesHelix BioPharma: Innovating with Purpose, Delivering with Urgency for a New Era in OncologyApril 26, 2025 | usatoday.comHelix Biopharma Corp. Announces Issuance of U.S. PatentNovember 23, 2024 | stockhouse.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 3, 2025 | Timothy Sykes (Ad)Helix BioPharma Reports Fiscal Loss, Refocuses StrategyOctober 25, 2024 | markets.businessinsider.comHBP:CA Helix BioPharma Corp.August 3, 2024 | seekingalpha.comHelix Biopharma: Fiscal Q2 Earnings SnapshotMay 13, 2024 | washingtonpost.comCanadian Investment Regulatory Organization Trading Halt - HBPMarch 28, 2024 | ca.finance.yahoo.comHelix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 10, 2023 | finance.yahoo.comSee More Headlines HBP Stock Analysis - Frequently Asked Questions How have HBP shares performed this year? Helix BioPharma's stock was trading at C$0.89 at the beginning of the year. Since then, HBP shares have increased by 7.9% and is now trading at C$0.96. View the best growth stocks for 2025 here. How were Helix BioPharma's earnings last quarter? Helix BioPharma Corp. (TSE:HBP) announced its earnings results on Thursday, October, 24th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter. How do I buy shares of Helix BioPharma? Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Helix BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU). Company Calendar Last Earnings10/24/2024Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:HBP CIKN/A Webwww.helixbiopharma.com Phone+1-416-9253232FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-50,548,392.71 Net MarginsN/A Pretax MarginN/A Return on Equity1,803.57% Return on Assets-279.98% Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio1.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.08 per share Price / Cash Flow11.32 Book ValueC($0.14) per share Price / Book-6.90Miscellaneous Outstanding Shares53,021,500Free FloatN/AMarket CapC$50.90 million OptionableNot Optionable Beta-0.84 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (TSE:HBP) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.